Genomics

#Drug discovery #Genomics #OutSee

OutSee raises £2.5m and partners with o2h discovery 

Genomic and drug discovery company OutSee has closed a £2.5 million ($3.4 million) seed funding round and partnered with contract research organisation o2h discovery to develop a lead drug target candidate.  The partnership aims to launch a collaborative drug discovery programme for OutSee’s lead target candidate, identified through the company’s genomic target discovery and precision medicine… Read More

#Business & Investment #News

AI and genomics
#AI / data analytics / healthtech / informatics #Genetics / genomics #Genomics #Market reporting

How are innovations in genomics redefining drug discovery?

Advances in artificial intelligence and synthetic biology are driving a new frontier in genomic research. Megan Thomas explores what the future of genomics will look like. New technologies for the future In a Eureka! podcast interview with McKinsey, Howard Jacob, Vice President of Genomics Research and Head of Data Integration… Read More

#Exclusive Content #Market Reports

Synthetic DNA
#Drug development #Genomics #Precision medicine

6-Base sequencing: A tool for better drug development 

Tom Charlesworth, Director of Marketing Strategy and Corporate Development at biomodal examines how 6-base sequencing can unlock advancements in precision medicine.  Call it precision medicine, Genomics 3.0, or the age of multi-omics. However you choose to describe it, the underlying meaning is the same: Our ability to collect and analyse… Read More

#Exclusive Content

#Genetics / genomics #Genomics #Market reporting

How are advances in genomics reshaping drug development?

Megan Thomas provides overview of the global market for genomics, covering its rapid reshaping of drug discovery and development to offer faster, more precise, and cost-effective pathways to new therapies while driving global collaboration and innovation. Past to present As far back as 2000, academic experts were writing in journals… Read More

#Exclusive Content #Market Reports

Human liver
#Genomics #GSK #Liver disease #Ochre Bio

Ochre Bio and GSK complete early research into human liver 

Biotechnology company Ochre Bio has completed research into human liver functional genomics and single-cell datasets, following a partnership with GSK.  Results include a large-scale functional genomics data from research into primary human hepatocytes and a single-cell dataset built from perfused human donor livers.  Ochre’s research… Read More

#News

Enzymes
#Artificial intelligence (AI) #Enzymes #Genomics

IDT and Profluent Bio partner on AI-driven next-gen enzymes

Genomics company Integrated DNA Technologies (IDT) has announced a strategic partnership with AI-first protein design Profluent Bio to design and optimise next-generation enzymes.  The collaboration will bring together Profluent’s generative AI platform with IDT’s expertise in enzymology and genomics, with the aim of exploring new paths for developing novel enzyme… Read More

#Business & Investment #News

Genomics
#Data #Drug discovery #Genomics #Multi-omics

Advancing drug discovery through multiomics  

John Lepore, MD, CEO of ProFound Therapeutics, explore how multiomics, combined with artificial intelligence and real-world data is advancing drug discovery. The drug discovery landscape is undergoing a transformative shift, driven by the growing demand for precision medicine and tremendous technological advances that inform systems biology. Traditional R&D approaches that… Read More

#Exclusive Content

London skyline
#CRISPR #CRISPR screening #Drug discovery #Genomics #Oncology

Registration open for DDW Symposium in London 

Registration is now open for the DDW Turning Science into Business Symposium. It will take place at the Francis Crick Institute in London on 4 November 2025.   Register here for tickets.  The half day event boasts a stellar line up… Read More

#News

#Drug discovery #Foundational model #Genomics #Large language model (LLM) #Machine learning #Merck #Open source

Merck shares foundation model with the research community

Merck is expanding access to TEDDY (Transformers for Enabling Drug DiscoverY), its foundation model for drug discovery, by adding it to HuggingFace, the premier platform for open-source machine learning and LLMs.  TEDDY was created in partnership with the Boston Consulting Group (BCG) AI Science Institute and is… Read More

#News

#Drug discovery #Drug targets #Enhanced Genomics #Genomics #Multi-omics

Part 2: A day exploring Cambridge’s life science scene

DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with several local companies and attended events. The first of this series was a conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. Here, DDW summarises what was learnt about Enhanced… Read More

#Exclusive Content

AAV gene therapy
#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Improve confidence in your vector batch profiling for gene therapies

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Human adenovirus
#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Webinar: Gain deeper insights into AAV products

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Webinar: Genomics solutions for gene therapy development

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Webinar: Rapid, comprehensive AAV genomic profiling made simple

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genomics #Nanopore sequencing

What’s in your gene therapy product? Rapid, comprehensive AAV genomic profiling made simple

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus for an expert-led webinar, hosted by DDW, showcasing new and improved genomics solutions… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

#GeneDx #Genetics / genomes #Genomics #PacBio

New study cracks genomic challenge: Paralogous genes

A newly published study in Nature Communications unveils a powerful new method for analysing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilises Paraphase, an informatics tool that, when paired with HiFi long-read… Read More

#News